Company Update (NYSE:AGN): Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program

[PR Newswire] – Under the terms of the agreement, Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million . . . → Read More: Company Update (NYSE:AGN): Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program Similar Articles: Company Update: Allergan Inc (NYSE:AGN) – Allergan to Acquire Oculeve Dry Eye Disease Development Programs Stock Update: Raytheon Co (NYSE:RTN) – U.S. Air Force marks significant progress with high-bandwidth satellite terminal development program Stock Update: Allergan Inc (NYSE:AGN) – FDA Approves Allergan’s NATRELLE INSPIRA™ Round Gel-Filled Breast Implants